Merck Evolves Human Health Operating Structure to Support Portfolio Execution

Merck Restructures for Growth: Oncology and Specialty Units Take Center Stage

Merck (NYSE: MRK) is strategically reshaping its Human Health organization, splitting it into two distinct business units: Oncology and Specialty, Pharma & Infectious Diseases. This move, announced on February 23, 2026, signals a proactive approach to navigating a changing pharmaceutical landscape and maximizing the potential of its robust pipeline.

A Response to the Keytruda Patent Cliff?

While not explicitly stated as the sole driver, the restructuring arrives as Merck prepares for the eventual loss of patent exclusivity for its blockbuster cancer drug, Keytruda. The company anticipates more than 20 new growth drivers in the coming years, and this organizational shift aims to ensure strong commercial execution across a more diversified portfolio.

New Leadership Appointments

Jannie Oosthuizen has been appointed Executive Vice President and President, Oncology and MSD International. He previously led Merck Human Health U.S., bringing extensive global marketing expertise in oncology. Brian Foard joins Merck as Executive Vice President and President, Specialty, Pharma & Infectious Diseases, transitioning from Sanofi where he oversaw a diverse specialty care portfolio. Both will report directly to Chairman and CEO Robert M. Davis and join the company’s executive team.

Sharpening Focus for Commercial Success

The creation of these dedicated units is designed to sustain long-term leadership in oncology while simultaneously bolstering launches across a broader range of therapeutic areas. Merck is currently engaged in approximately 80 Phase 3 studies, indicating a significant investment in future innovation.

Strategic Access, Policy & Communications Integrated

Merck is also integrating access, policy, communications, and sustainability into a single organization led by Chirfi Guindo, Executive Vice President, Strategic Access, Policy & Communications. This aims to strengthen alignment between strategy and execution, and improve stakeholder engagement.

What This Means for Patients and Stakeholders

According to Robert M. Davis, the restructuring is about “delivering innovative medicines for patients and creating long-term value for our stakeholders.” The company emphasizes its commitment to scientific leadership and shaping the future of medicine.

FAQ

• What are the new business units at Merck? Merck has created an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit.
• Who is leading the Oncology Business Unit? Jannie Oosthuizen is the Executive Vice President and President of the Oncology and MSD International unit.
• Who is leading the Specialty, Pharma & Infectious Diseases Business Unit? Brian Foard is the Executive Vice President and President of this unit.
• Why is Merck making these changes? To ensure strong commercial execution of launches and position the company for continued success as its pipeline diversifies.

Pro Tip: Keep an eye on Merck’s pipeline announcements. With over 80 Phase 3 studies underway, the company is poised to introduce several new therapies in the coming years.

Explore more about Merck’s research and development efforts on their website.